Because the most characteristic property of ovarian cancer is i.p. spread, the majority of patients are diagnosed at an advanced stage, leading to limited availability of options for curative therapies. With an intent to identify targeted therapeutic approaches, we have observed that f60% of 21 ovarian cancer tissue samples express a high density of interleukin-4 receptor (IL-4R), whereas normal ovarian tissues tested (n = 7) expressed no or low levels of IL-4R. To target IL-4R, we have developed IL-4 cytotoxin, in which circularpermuted IL-4 is fused to a mutated form of Pseudomonas exotoxin. This cytotoxin is specifically and highly cytotoxic to PA-1, IGROV-1, and SK-OV3 ovarian carcinoma cell lines in vitro. In addition, it shows remarkable antitumor activities against established s.c. ovarian tumors in immunodeficient animals. i.p. administration of IL-4 cytotoxin in mice with orthotopically implanted ovarian tumors caused regression of established tumors and prevented these animals from tumor metastasis. Continuous i.p. infusion of IL-4 cytotoxin prolonged survival of tumor-bearing mice even with bulky disease. These results indicate that IL-4R-targeted cytotoxin may be a useful agent for the management of patients with ovarian cancer, and further studies need to be done to evaluate its safety, tolerability, and efficacy. (Cancer Res 2005; 65(18): 8388-96) 
Introduction
Ovarian carcinoma is the fifth leading cause of cancer-related deaths in females and the leading cause of death from gynecologic malignancy in the U.S. Approximately 14,700 patients died in the year 2002 alone. The overall 5-year survival rate of ovarian cancer patients is 30% to 50%, as the majority of these patients are diagnosed at an advanced stage (III or IV) of the disease, at which time the primary tumor has metastasized (1, 2) . One of the characteristics of the malignancy of ovarian cancers is their invasion and metastatic potential. In most cases, the spread of cancer is through the i.p. route. Therefore, i.p. administration of chemotherapy is a logical approach for ovarian cancer therapy. The first such trial involving i.p. administration of cisplatin-based chemotherapy revealed an improved effect in both survival and toxicity, however, toxicities by the i.p. route were higher compared with the i.v. route (3, 4) . Additional therapeutic approaches are needed for effective management of patients with ovarian cancer.
Interleukin-4 (IL-4) is an important Th2-derived cytokine, which is involved in mediating numerous antitumor immune-modulating activities (5) . It is a key cytokine involved in IgG, IgE, and MHC class II expression, the generation of dendritic cells, and tumorreactive CTLs. In addition, IL-4 causes direct inhibition of cancer cell growth in vitro (6, 7) . Because of these properties, IL-4 was tested in the clinical trials for hematopoietic and some solid malignancies (8, 9) . As IL-4 mediated limited antitumor activity, most clinical trials were aborted. Another characteristic of IL-4 and host interaction through IL-4 receptor (IL-4R) have been explored in recent years as a large number of hematopoietic and solid human tumors express IL-4R in vitro and in vivo (10) (11) (12) . To target IL-4R on human tumors, we have developed a fusion protein, IL-4 cytotoxin, which is composed of a circularly permuted IL-4 and a mutated form of a powerful bacterial toxin (Pseudomonas exotoxin). After binding to IL-4R on the cell surface, IL-4 cytotoxin internalizes into an endosome with the IL-4R, translocates to the cytosol, and then ribosylates elongation factor 2 to prevent the initiation of protein synthesis, leading to cell death. IL-4 cytotoxin, termed IL4(38-37)-PE38KDEL, has shown remarkable antitumor activity in vitro and in vivo against a variety of human tumors (12) (13) (14) (15) . Because of these activities, this molecule has been tested in the clinic in patients with malignant glioma, and advanced solid tumors (16) (17) (18) . We have also shown that two ovarian cancer cell lines, PA-1 and IGROV-1, express IL-4R on their cell surface (19) . However, expression of IL-4R in human ovarian cancer specimens is not known. As IL-4 cytotoxin can be administrated by i.p. route, here we have examined whether ovarian cancer specimens and normal ovary tissue samples express IL-4R and whether these receptors can be targeted by IL-4 cytotoxin.
We report that a great majority of ovarian cancer specimens (f60%) overexpress IL-4R. In contrast, normal ovary tissue samples do not express IL-4R or express at very low frequency. IL-4R on ovarian cancer cells can be targeted by IL-4 cytotoxin in vitro and in vivo in mouse models of ovarian cancer.
Materials and Methods
Cell culture and reagents. The human PA-1, SKOV-3, and OVCAR-3 cell lines were purchased from the American Type Culture Collection (Manassas, VA) and cultured as described previously (20, 21 (23) . Quantification of IL-4Ra mRNA expression levels in ovarian cancer cell lines was determined by real-time reverse transcription-PCR using a set of IL-4Ra-specific TaqMan probe (5V-FAM, 3V-MGB) and primers (Applied Biosystems, Foster City, CA). Total RNA was reverse transcribed into the cDNA primed with oligo-dT. Quantitative PCR reactions were done using the ABI PRISM 7700 sequence detection system (Applied Biosystems). cDNA (50 ng) was added to a reaction volume (30 AL) containing 1Â TaqMan PCR master mix, IL-4Ra-specific probe/primers set, and glyceraldehyde-3-phosphate dehydrogenase or h-actin-specific probe (5V-VIC, 3V-MGB)/primers mix (Applied Biosystems). Gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase or h-actin before the fold change in gene expression was calculated.
Protein synthesis inhibition assay. The in vitro cytotoxic activity of IL-4 cytotoxin was measured by the inhibition of protein synthesis (24) . Briefly, cells (1 Â 10 4 ) were cultured in leucine-free medium with or without various concentrations of IL-4 cytotoxin for 22 hours at 37jC. Then 1 ACi of [ ) was calculated by multiplying length and width of tumor on a given day. Treatments were started 6 days after inoculation when the tumors reached a mean size of 30 mm 2 (5-6 mm diameter). Mice were randomly divided into different therapeutic groups and one control group (six to seven mice per group). Mice were given injections of excipient (0.2% human serum albumin in PBS) or IL-4 cytotoxin by either i.p. (500 AL with 27-gauge needle) or intratumoral (i.t.; 30 AL with microinjection syringe) routes. To determine the sensitivity of regrown PA-1 s.c. tumors to IL-4 cytotoxin, PA-1 tumors treated with 50 Ag/kg dose of IL-4 cytotoxin were excised at day 60, digested with collagenase and DNase, and cultured. After two passages, the sensitivity of the cells to IL-4 cytotoxin was determined by protein synthesis inhibition assays.
Orthotopic xenograft ovarian tumor model. For the orthotopic model, tumor chunks obtained from s.c. growing tumors were minced and 1 Â 1 mm pieces were sutured and implanted in the right ovary under anesthesia. Tumor volume (V ) was calculated using the formula:
where L is the length of the tumor in millimeters, and W is the width of the tumor in millimeters (25) . Treatments were started either 5 or 15 days after inoculation when the tumors were established or started to spread their invasion, respectively. Mice were randomly divided into different therapeutic groups and one control group. Animals were given i.p. injections of excipient (0.2% human serum albumin in PBS) or IL-4 cytotoxin by continuous infusion pump with 50 or 500 Ag/kg/d dosage for 14 days.
Statistical analysis. The statistical significance of data was calculated by Student's t test. All statistical tests were two-sided. Survival probabilities were estimated by Kaplan-Meier methods. For analysis of statistical significance between the therapeutic group and control group in survival assay, log-rank test was used.
Results
Expression of IL-4 receptor in ovarian tumor tissues. Tissue sections from 7 normal ovary and 21 ovarian tumor samples were analyzed by immunohistochemical analysis for the expression of IL-4R. The expression of IL-4Ra chain, which is a predominant IL-4 binding protein, was analyzed (26) . Some of the tumor specimens showing high levels of IL-4Ra expression (sample numbers 1 and 21) are presented in Fig. 1A . In contrast to cancer tissues, normal ovary tissue specimens showed no staining to weakly positive (+, +/À) staining for IL-4Ra chain (Fig. 1A , sample number 22). The expression level of IL-4Ra chain and histology of ovarian cancer are summarized in Table 1 . Approximately 60% of ovarian tumor tissues expressed IL-4Ra chain at high density (++) and 33% at moderate density (+).
Ovarian cancer cell lines expressing IL-4R are sensitive to IL-4 cytotoxin. We next determined the expression of IL-4Ra mRNA by semiquantitative reverse transcription-PCR and TaqMan real-time reverse transcription-PCR analyses in five ovarian cancer cell lines. The expression of mRNA for IL-4Ra chain was not detected in OVCA-429 cell line, but all other ovarian cancer cell lines showed varied density of IL-4Ra mRNA expression by conventional semiquantitative reverse transcription-PCR analysis (data not shown). Real-time reverse transcription-PCR confirmed conventional reverse transcription-PCR results and showed that SK-OV3 cell line expresses highest level of IL-4Ra mRNA, followed by PA-1, IGROV-1 and OVCAR-3 cell lines (Fig. 1B) .
Sensitivity of ovarian cancer cell lines to IL-4 cytotoxin was tested by protein synthesis inhibition assays. As shown in Fig. 1C , the PA-1 cell line was extremely sensitive to IL-4 cytotoxin (IC 50 = 0.2 ng/mL), followed by IGROV-1 (IC 50 = 2 ng/mL), SK-OV3 (IC 50 = 10 ng/mL), and OVCAR-3 (IC 50 = >1,000 ng/mL). Although the SK-OV3 cell line expressed the highest level of IL-4Ra mRNA, IL-4 cytotoxin showed moderate cytotoxicity in this cell line. With this exception, the expression level of IL-4Ra mRNA correlated with sensitivity to IL-4 cytotoxin in all other ovarian cancer cell lines.
Intraperitoneal administration of IL-4 cytotoxin inhibits ovarian tumor growth. We investigated the effect of IL-4 cytotoxin in s.c. xenografted human ovarian tumor in nude mice. We injected IL-4 cytotoxin (50 or 200 Ag/kg Â 5 days) i.p. twice daily in PA-1, SK-OV3, or OVCAR-3 tumor-bearing mice (n = 6). The IL-4 cytotoxin treatment started on day 6 as palpable tumors developed within 3 to 4 days. As shown in Fig Intratumoral administration of IL-4 cytotoxin eradicates ovarian tumors. We next evaluated the effect of IL-4 cytotoxin in three different ovarian tumor models, selected based on their sensitivities to IL-4 cytotoxin in vitro. s.c. xenografted tumor-bearing mice (six mice per group) were treated i.t. with three injections of IL-4 cytotoxin. Interestingly, IL-4 cytotoxin treatment (125 or 500 Ag/ kg/d) on alternate days for 3 days eradicated PA-1 s.c. tumors in two out of six mice and in four out of six mice at low and high dose, respectively (Fig. 2B) . The residual small tumors in the higher or lower dose groups did not show regrowth by day 44 of follow up. However, the tumors in control mice continued to grow exponentially, and mice were sacrificed on day 49 due to large tumor burden. The overall reduction in tumor size was 89% in the 125 Ag/kg (P < 0.001) and 97% in the 200 Ag/kg (P < 0.001) dose groups. Although IL-4 cytotoxin treatment did not cause complete regression of SK-OV3 s.c. tumor by i.t. administration, all mice receiving 125 or 500 Ag/kg doses showed a significant regression of tumors (60%; P < 0.0001 or 80%; P < 0.0001 at low and high doses, respectively; compared with controls). On the other hand, OVCAR-3 tumorxenografted mice were resistant to IL-4 cytotoxin treatment, and average tumor sizes in both treatment groups were not significantly different from control group (P = 0.23). The efficacy of IL-4 cytotoxin by either i.p. or i.t. administration in three different xenografts seemed to correlate well with their cytotoxicity in vitro protein synthesis assays. Because both dosages (125 and 500 Ag/kg) of IL-4 cytotoxin mediated remarkable efficacy against PA-1 tumors, we next tested whether lower dosages of IL-4 cytotoxin could also mediate antitumor effects. As shown in Fig. 2C , IL-4 cytotoxin at the 50 Ag/kg dose still mediated strong antitumor activity, and one out of six mice showed complete regression of tumor. In addition, a 5 Ag/kg dose also significantly inhibited the tumor growth as compared with the control group (P < 0.001). After 45 days of observation, tumors in the 50 Ag/kg IL-4 cytotoxin dose group started to regrow slowly. To explore whether regrowth was caused by heterogeneity in IL-4Ra expression, development of resistance, or poor accessibility of IL-4 cytotoxin, PA-1 tumors in either control or IL-4 cytotoxin-treated groups were resected on day 60 and cultured in vitro, and their sensitivity to IL-4 cytotoxin was tested in vitro. As shown in Fig. 2D , tumor cells from control and IL-4 cytotoxin-treated mice maintained equal sensitivity to IL-4 cytotoxin. These results suggest that partial regression of tumors in PA-1 tumor model could be due to inadequate IL-4 cytotoxin distribution within the tumor mass rather than heterogeneity or tumor resistance to IL-4 cytotoxin.
Prevention of tumor metastasis by IL-4 cytotoxin therapy in orthotopic ovarian tumor model. The antitumor effect of IL-4 cytotoxin and the survival rate of mice orthotopically implanted with ovarian tumors were investigated to determine the efficacy of IL-4 cytotoxin in a model system that simulated a clinical situation for aggressiveness of cancer. PA-1 and IGROV-1 tumor chunks were orthotopically implanted on ovaries, and then tumor-bearing mice were injected with either excipient (control) or IL-4 cytotoxin (200 Ag/kg, twice a day for 5 days from days 5 to 9) through i.p. route. All tumor-bearing animals (n = 5) without treatment showed an aggressive tumor growth, invasion, and spread to other organs (Fig. 3) . As determined by macroscopic and microscopic analyses, ovarian tumors invaded other organs including liver, small intestine, ipsilateral kidney, and contralateral ovary in control mice (Fig. 3A-D and I-L) . The status of ovarian cancer spread to other organs 4 weeks after implantation of tumor is summarized in Table 2A . Untreated animals showed tumor metastasis outside the pelvic cavity. At the terminal stage, all untreated control tumorbearing mice showed ascites, which contained tumor cells as confirmed by Giemsa stain (Fig. 3M and N) . In contrast, no metastasis was observed in the IL-4 cytotoxin treatment group (Table 2A; Fig. 3E-H ; H&E stain not shown). In addition, tumor volumes at the tumor-implanted right ovaries were significantly smaller compared with the control group (P < 0.01) 4 weeks after implantation of tumor (Fig. 3O) .
Intraperitoneal IL-4 cytotoxin prevents cachexia and prolongs survival of mice implanted orthotopically with ovarian tumors. We also evaluated overall survival of IL-4 cytotoxintreated ovarian tumor-bearing mice. Mice orthotopically implanted with PA-1, SK-OV3, or IGROV-1 tumors ( five mice per group in PA-1 and IGROV-1, eight mice per group in SK-OV3) were treated with excipient only (control) or IL-4 cytotoxin (50, 100, or 200 Ag/kg twice daily for 5 days from days 5 to 9). As shown in Fig. 3P and Q, survival of mice was significantly extended in all treated groups (PA-1, P < 0.01; SK-OV3, P < 0.001; IGROV-1, P < 0.05-0.0001, compared with controls). At the highest IL-4 cytotoxin dose (200 Ag/kg), all IGROV-1 tumor-bearing mice survived for as long as we followed these animals (>200 days), whereas all untreated mice died in <100 days.
Orthotopically implanted IGROV-1 ovarian tumor-bearing mice showed substantial body weight loss and tumor progression with excipient treatment, whereas IL-4 cytotoxin-treated mice showed weight gain and tumor regression (Fig. 3R) . Mice body weight were measured at least once a week, and showed persistent weight loss in control mice along with tumor progression and invasion. After 4 weeks of implantation, body weight of control mice did not increase, gradually stabilized, and after 8 weeks, loss in body weight occurred despite the growth of tumors (Fig. 3R) . The IGROV-1 orthotopic tumor-harboring mice treated with 100 or 200 Ag/kg dose of IL-4 cytotoxin (Fig. 3Q) showed linear increase in body weight for the 12 weeks that we followed these animals. Interestingly, the 100 Ag/kg dose of IL-4 cytotoxin did not completely cure tumor-bearing animals, nevertheless, these animals also showed linear increase in body weight (Fig. 3R) .
IL-4 cytotoxin eradicates large s.c. ovarian tumors and has antitumor activity against orthotipically implanted ovarian cancer in an advanced tumor model. To evaluate the efficacy of IL-4 cytotoxin in advanced ovarian cancer models, we treated tumor-bearing mice (six mice per group) with IL-4 cytotoxin by i.p. or i.t. routes starting on day 19 when the PA-1 s.c. tumors grew to f75 mm 2 . Twice a day i.p. (200 Ag/kg) or daily i.t. (500 Ag/kg) injections of IL-4 cytotoxin for 10 days (5 days/wk), followed by a 7-day rest, formed the first cycle of treatment (Fig. 4A) . The tumors began to regress just after the first treatment cycle in both i.p. and i.t. treatment groups. Both groups of animals also received a second cycle of treatment on days 25 to 29 by the i.t. route and on days 32 to 36 by the i.p. route. The tumor regression continued after treatment was completed, and four out of six mice showed complete regression of their tumors in the i.t. treatment group. i.p. treatment also showed statistically significant antitumor activity (P = 0.0003, versus control); however, complete regression of tumors was not observed.
Encouraged by the therapeutic effect of IL-4 cytotoxin in s.c. and orthotopic ovarian tumor models, we next determined the efficacy of IL-4 cytotoxin in advanced orthotopic ovarian tumor model. We started the injection of IL-4 cytotoxin 15 days after implantation of IGROV-1 ovarian tumor on the right ovary. As shown in Fig. 4B , i.p. treatment of IL-4 cytotoxin caused regression of tumor growth in implanted right ovary. At 500 Ag/kg dose, a dramatic reduction in tumor volume was observed. The average tumor volumes in 50 and 500 Ag/kg/d doses were 59% (P < 0.02) and 99% (P = 0.009) of controls, respectively, on day 43. The status of ovarian cancer spread to other organs 6 weeks after implantation of tumor is summarized in Table 2B . Ovarian tumors invaded the liver, small intestine, and ipsilateral kidney in all control mice (three mice per group). In contrast, no metastasis was observed in the 500 Ag/kg/d IL-4 cytotoxin-treated group. An IL-4 cytotoxin dose of 50 Ag/kg/d showed metastasis to liver and kidney, but not in all animals.
Consistent with the regression of established tumors, the survival of advanced orthotopic ovarian tumor-bearing mice (nine mice per group) was also extended in 500 Ag/kg/d IL-4 cytotoxintreated animals compared with controls (P < 0.001). The 50 Ag/kg/d dose showed tumor regression, however, this regression was not enough to statistically prolong significant survival from aggressive tumor growth (Fig. 4C) . Median survival time was 85 days (range, 56-95 days; n = 9) in the control group, 93 days (range, 72-112 days; n = 9) in the 50 Ag/kg dose group, and 137 days (range, 91-180, experimental period, days; n = 9) in the 500 Ag/kg dose of IL-4 cytotoxin. These data indicate that i.p. administration of IL-4 cytotoxin is effective in the regression of large ovarian tumors as well as in the prevention of metastasis of advanced orthotopic ovarian tumors.
Discussion
Despite advances in surgery and chemotherapy, long-term survival of patients with stage III or IV ovarian cancer is limited due to i.p. spread of tumor cells at diagnosis, for which no curative therapy is available (27) . To develop novel therapeutic approaches, in this study, we show that f60% ovarian tumor samples overexpress IL-4R at high levels and 33% of ovarian tumor samples at moderate levels. As normal ovarian tissues expressed no or low levels of IL-4R, our results indicate that IL-4R might be a tumor-associated target for ovarian tumor therapy. We exploited this property of epithelial ovarian tumors and observed that IL-4R-positive ovarian tumor cell lines are highly sensitive to the cytotoxic effect of IL-4 cytotoxin in vitro, which targets IL-4R. The sensitivity of these tumor cell lines to IL-4 cytotoxin approximately correlated positively with the density of IL-4Ra mRNA expression.
This promising antitumor activity of IL-4 cytotoxin was also tested in vivo in animal models of human ovarian tumors. We selected three tumor cell lines expressing high, moderate, and low levels of IL-4R. Consistent with varied receptor expression, these cell lines showed high, intermediate, and low sensitivity to IL-4 cytotoxin in vitro. Antitumor effect in vivo was first analyzed in s.c. tumor models. We observed that i.p. and i.t. administration of IL-4 cytotoxin to tumor-bearing mice mediated dramatic antitumor effects by causing regression of tumors in a dose-dependent manner. Similar to in vitro effects, IL-4 cytotoxin mediated the highest antitumor activity against PA-1 tumors followed by SK-OV3 tumors. Limited antitumor activity was seen against OVCAR-3 tumors. These results show that IL-4 cytotoxin can mediate profound antitumor effects in ovarian tumors.
Because ovarian tumors metastasize to the peritoneal cavity, local therapy as a first line or as an adjuvant may be a useful approach. i.p. administration of targeted agents such as IL-4 cytotoxin may cause a therapeutic impact without toxicity to normal organs. To test this hypothesis, we developed the orthotopic tumor model by surgically implanting PA-1 tumor chunks on the These observations indicate that IL-4 cytotoxin not only causes regression of established orthotopic ovarian tumor but it also prevented ascites formation and tumor metastasis. This is a remarkable observation very rarely seen with other therapeutic approaches.
The remarkable anti-ovarian tumor effects of IL-4 cytotoxin were further confirmed by enhanced survival of treated animals. When treated with IL-4 cytotoxin, the most sensitive tumor-bearing hosts showed statistically significant (P < 0.05) survival compared with control animals in a dose-dependent manner. At the highest dose, all treated animals survived for as long as we followed these animals. Less sensitive tumor (SK-OV3)-bearing hosts also showed statistically significant survival compared with untreated control animals. Although the PA-1 tumor cell line showed the highest sensitivity in vitro and in vivo s.c. tumor model to IL-4 cytotoxin, these orthotopic tumor-bearing mice showed statistically significant prolonged survival compared with control, but not longer expected survival compared with other tumor-bearing mice (SK-OV3 and IGROV-1). One of the possible reasons might be the extreme aggressiveness of this tumor. All mice bearing PA-1 tumors in the control group died within 60 days of implantation compared with SK-OV3 and IGROV-1 tumor-bearing mice which died in >80 days.
For clinical application of IL-4 cytotoxin, several considerations in terms of feasibility of delivery and toxicity are of paramount importance. Previous studies of ours as well as others have shown that IL-4R is expressed on normal immunologic and nonhematopoietic cells. However, IL-4 cytotoxin is not very cytotoxic to these cells as they express no or low levels of IL-4R (14, 28, 29) . Preclinical toxicity studies in mice have shown that IL-4 cytotoxin is welltolerated up to 475 Ag/kg dose given i.v. (30) . As human IL-4 does not bind murine IL-4R, IL-4 cytotoxin was also injected to cynomolgus monkeys, whose IL-4R binds human IL-4. In these animals, IL-4 cytotoxin was reasonably tolerated up to a dose of 200 Ag/kg given i.v. every alternate day for three injections. 4 Reversible liver enzyme elevation and injection site inflammatory reactions were observed. These reversible preclinical observations were also observed in a small phase I clinical study, in which IL-4 cytotoxin caused dosedependent hepatic enzyme elevation when given i.v. (18) . As normal ovarian cells do not express high density of IL-4R and IL-4 cytotoxin does not mediate any other toxicity, including renal toxicity, it is possible that i.p. administration of IL-4 cytotoxin in patients with ovarian tumors would be better tolerated. In that regard, it is important to note that in two phase I clinical trials in which IL-4 cytotoxin was injected intracranially by convection enhanced delivery directly into glioma tumors, this molecule was tolerated with acceptable neurologic and no systemic toxicities (16, 17) .
Regarding the route of administration, perhaps i.p. delivery by catheter, similar to Tenckhoff, would be a feasible approach. To address whether this route would be tolerated, we delivered IL-4 cytotoxin continuously by i.p. pump for a period of 14 days and 
A, metastasis of PA-1 orthotopic ovarian tumors into other organs was observed by macroscopic and microscopic analysis 4 weeks after implantation onto the right ovary. B, metastasis of IGROV-1 orthotopic ovarian tumors into other organs was observed macroscopically and microscopically 6 weeks after implantation onto the right ovary. *À, negative metastasis; +, positive metastasis.
survival of IGROV-1 tumor-bearing mice were followed. None of these animals showed any visible signs of toxicity, however, statistically significant (P < 0.001) prolonged survival of IL-4 cytotoxin-treated animals at higher dose was observed. This observation is important, providing a proof of principle for continuous i.p. delivery of IL-4 cytotoxin for metastatic ovarian tumor. Several molecules targeting ovarian cancer are under development. These targets include epidermal growth factor receptor (EGFR), p53 pathway, TRAIL, BCL-2 family, and vascular endothelial growth factor (31) (32) (33) (34) (35) . Clinical trials are ongoing, evaluating agents that inhibit vascular endothelial growth factor or EGFR signaling pathways in ovarian cancer (36, 37) . Ovarian carcinomas (30-70%) express high levels and EGFR expression correlates with the survival of these patients (38, 39) . Because the frequency of IL-4R expression in human ovarian cancer specimens archived is comparable to the expression of EGFR, it is possible that IL-4R may also serve as a biomarker for prognosis or as a target for other approaches other than IL-4 cytotoxin. Additional tumor samples need to be evaluated to confirm this hypothesis.
It is important to note that IL-4 cytotoxin treatment also prevented development of cachexia in tumor-bearing animals. A persistent weight loss in IGROV-1 orthotopic tumor-harboring mice was observed along with the progression of tumor growth and invasion. In sharp contrast, tumor-bearing mice treated with IL-4 cytotoxin showed linear increase in body weight in a dosedependent manner along with tumor regression. These observations suggest that body weight may serve as a biomarker for tumor response in ovarian tumor-bearing animals. Further studies are needed to confirm this hypothesis. However, thus far, few agents (except IL-4 cytotoxin) have shown a convincing antitumor effect in advanced ovarian cancer models. Thus, IL-4 cytotoxin may be expected to be useful for patients with advanced ovarian cancer.
In conclusion, our studies show that IL-4 cytotoxin has notable antitumor activity against ovarian tumor that express IL-4R. To our knowledge, this is the first report in which orthotopic ovarian tumors were completely eradicated by IL-4R-targeted therapy in animal model. Because in vitro cytotoxicity of IL-4 cytotoxin has revealed positive correlation with in vivo antitumor activity in animal models, it is expected that the efficacy of IL-4 cytotoxin may be realized in clinical situations. 
